- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12.25 | Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential | 3 | Investing.com | ||
| 17.12.25 | Upstream Bio: Mizuho startet Coverage mit "Outperform" dank Potenzial bei Asthma-Medikament | - | Investing.com Deutsch | ||
| 05.11.25 | Upstream Bio, Inc. reports Q3 results | 2 | Seeking Alpha | ||
| 05.11.25 | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | 221 | GlobeNewswire (Europe) | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| 05.11.25 | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10.25 | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 3 | Investing.com | ||
| 14.10.25 | Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential | 2 | Investing.com | ||
| 14.10.25 | Upstream Bio: Truist Securities startet Coverage mit Kaufempfehlung dank Potenzial bei Atemwegsmedikament | 1 | Investing.com Deutsch | ||
| 30.09.25 | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | 419 | GlobeNewswire (Europe) | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| 09.09.25 | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 02.09.25 | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09.25 | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 8 | RTTNews | ||
| 26.08.25 | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 2 | Investing.com | ||
| 08.07.25 | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | 348 | GlobeNewswire (Europe) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| 20.05.25 | Upstream Bio Appoints Stacy Price as Chief Technology Officer | 188 | GlobeNewswire (Europe) | WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
| 01.04.25 | Pre-market Movers: Marblegate Acquisition Corp., iCoreConnect, Hyperscale Data, Upstream Bio, InnovAge Holding | 605 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green Marblegate Acquisition Corp. (GATE) is up over 55%... ► Artikel lesen | |
| 12.03.25 | Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 211 | GlobeNewswire (Europe) | - Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 - - Completed upsized IPO... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
Das Unternehmen UPSTREAM BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 26,200 Euro und damit +0,77 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.